Financing will support the full execution of Phase Ib proof-of-mechanism study of MTX325 in patients with Parkinson’s disease (PD) Comes after successful completion of Phase 1a studies of MTX325, a first-in-class and potentially disease-modifying treatment […]
Financing will support the full execution of Phase Ib proof-of-mechanism study of MTX325 in patients with Parkinson’s disease (PD) Comes after successful completion of Phase 1a studies of MTX325, a first-in-class and potentially disease-modifying treatment […]
